4/A: Aldeyra Therapeutics Executive Sells Shares to Cover Tax Obligations, Amends Previous Filing

Bruce Greenberg, Interim CFO of Aldeyra Therapeutics, sold shares to cover tax obligations and amended a previous filing to correct an omission regarding shares acquired through the Employee Stock Purchase Plan.

Summary

• Bruce Greenberg, Interim Chief Financial Officer of Aldeyra Therapeutics, sold 13,201 shares of common stock on March 11, 2024, at a weighted average price of $3.4064 per share.
• The sale was executed to cover tax withholding obligations upon the settlement of time-based restricted stock unit awards.
• This transaction was initially reported in a Form 4 filing on March 12, 2024, which this Form 4/A amends.
• The amendment corrects an omission of 9,455 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan.
• Following the reported transaction and the adjustment, Greenberg beneficially owns 130,154 shares of Aldeyra Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to insider trading. It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for executives at publicly traded companies. The sale appears to be related to tax obligations, which is a typical reason for such transactions.

Key Dates